spacer
home > pmps > autumn 2018 > consumer communication
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Consumer Communication

When thinking about pharmaceutical packaging, boxes of pills with unpronounceable brand names that are sterile and prescriptive in appearance, with bulky pamphlets full of information on side effects and dosages fitted inside spring to mind. This is a particularly uninspiring image, and it makes it easy to understand why, from a patient or consumer point of view, there is very little to engage with. If a consumer is unable to differentiate between one medication and another, they would have no reason to base their decision on anything more than cost or habit. This article will explore the ways in which companies can stand out from competitors and looks to engage with patients on a level that will mean they automatically select one brand over another.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Vicki Young is CEO and Founder of Nalla Design, a branding and design agency based in London, UK. She studied graphic design at Kingston University, UK, graduating in 2006 and earning two Design and Art Direction Yellow Pencils. Vicki worked as a designer at the agencies SomeOne and The Partners, before founding Nalla Design in 2010.
spacer
Vicki Young
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Novo Nordisk Pharmatech A/S signs distribution agreement with DKSH for twelve countries in Asia Pacific

Novo Nordisk Pharmatech A/S and DKSH, have partnered to provide high-quality cGMP quaternary ammonium compounds in twelve countries across Asia Pacific
More info >>

White Papers

The Flexible Factory Concept: A flexible bioprocessing platform to meet the changing needs of biomanufacturing

GE Healthcare Life Sciences

For the past several years, the biopharma industry has been buffeted by dynamic market conditions that are rapidly reshaping manufacturing requirements. These factors include: • The rise of small-market pharmaceuticals that do not require the production scale of the previous “blockbuster” drug model • Increased titers and process productivity that generate more bulk-product within a much smaller manufacturing footprint • The emergence of biosimilars and continued evolution of healthcare reform, which will increasingly pressure drug pricing and require greater cost discipline • Greater competition and shorter patent protection timelines, which will further ratchet up time-to-market pressures • Tighter capital markets that will create heightened scrutiny for all new investment projects
More info >>

 
Industry Events

PDA Europe Annual Meeting 2019

24 June 2019, Hilton Amsterdam

Featuring updates from international regulatory agencies as well as industry, this promises to become another highlight in the 2019 event calendar and is a meeting not to be missed!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement